A securities class action has been filed in the USDC – CD.CA. against Alexandria Real Estate Equities, Inc. (ARE) (“Alexandria” or the “Company”), on behalf of all persons and entities that purchased or otherwise acquired Alexandria securities between January 27, 2025, and October 27, 2025, both dates inclusive (the “Class Period”).
Alexandria is a real estate investment trust (REIT) specializing in life-science real estate with a focus on lab space, research facilities and offices for tenants in the pharmaceutical, biotech, and agricultural technology industries. Alexandria owns, operates and develops collaborative Megacampus™ ecosystems in life science innovation cluster locations including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City.
The complaint alleges defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of its Long Island City (LIC) property; notably, the Company’s claims and confidence about the leasing value of the LIC property as a life-science destination aligning with ARE’s MegacampusT strategy.
From a closing market price of $77.87 per share on October 27, 2025, Alexandria’s stock price fell to $62.94 per share on October 28, 2025, a decline of about 19% in the span of just a single day.
If you purchased Alexandria securities during the Class Period, and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.